12:00 AM
 | 
Oct 07, 2013
 |  BioCentury  |  Finance

Deciphering GenomeDx

Reimbursement plan key to GenomeDx's financings
Deciphering GenomeDx

While some investors are fleeing the diagnostic space, a series B round for GenomeDx Biosciences Inc. shows there is money out there for companies with a path to reimbursement.

The size of the round is undisclosed. It was led by Merck Global Health Innovation Fund (GHIF) and...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >